Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
Condition(s):Dermatomyositis; Juvenile DermatomyositisLast Updated:September 16, 2021Completed
Hide Studies Not Open or Pending
Condition(s):Dermatomyositis; Juvenile DermatomyositisLast Updated:September 16, 2021Completed
Condition(s):Rheumatoid ArthritisLast Updated:September 6, 2023Completed
Condition(s):Multiple Sclerosis (MS)Last Updated:September 16, 2014Completed
Condition(s):Dermatomyositis; PolymyositisLast Updated:September 1, 2017Completed
Condition(s):ScleritisLast Updated:October 23, 2023Recruiting
Condition(s):Treatment Resistant Nephrotic SyndromeLast Updated:April 24, 2014Completed
Condition(s):Fibrillary GlomerulonephritisLast Updated:October 31, 2022Active, not recruiting
Condition(s):Lupus Erythematosus Systemic ExacerbationLast Updated:July 23, 2013Completed
Condition(s):Multiple SclerosisLast Updated:September 6, 2017Unknown status
Condition(s):Steroid-Resistant Nephrotic SyndromeLast Updated:April 23, 2019Withdrawn
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.